

## News Release

For release: 17 February 2023

### **ANZ allocates \$1.5 billion under ANZ Capital Notes 8 Bookbuild; Margin set at 2.75% p.a.**

Australia and New Zealand Banking Group Limited (**ANZ**) today announced that it had brought forward the ANZ Capital Notes 8 Bookbuild and has allocated \$1.5 billion of ANZ Capital Notes 8, with the Margin set at 2.75% per annum.

The ANZ Capital Notes 8 offer is being made under the prospectus lodged with ASIC on 15 February 2023 (**Prospectus**). A replacement prospectus reflecting the Margin and revised offer size will be lodged with ASIC on Thursday, 23 February and will be available within Australia at [capitalnotes.anz.com](http://capitalnotes.anz.com).

Investors applying for ANZ Capital Notes 8 should speak to their Syndicate Broker regarding their application, read the replacement prospectus in its entirety and will need to complete an application form accompanying the replacement prospectus. All applications must be made through a Syndicate Broker. A list of the Syndicate Brokers is contained in the Prospectus.

Capitalised terms have the meaning given to them in the Prospectus.

**For investor enquiries about the ANZ Capital Notes 8 Offer please visit [capitalnotes.anz.com](http://capitalnotes.anz.com) or call the ANZ Information Line on 1800 113 399 (within Australia) or +61 3 9415 4010 (international) (Monday to Friday – 8:30am to 5:30pm Melbourne time).**

For media enquiries only contact:  
Stephen Ries, Head of Corporate Communications +61 409 655 551

*Approved for distribution by ANZ's Continuous Disclosure Committee*

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES OF AMERICA. This announcement does not constitute financial product advice or an offer of any securities for sale. The securities referenced have not been and will not be registered under the U.S. Securities Act of 1933, as amended (Securities Act), or the securities laws of any state or jurisdiction of the United States and may not be offered, sold or resold, directly or indirectly, in the United States or to, or for the account or benefit of, any U.S. person (as defined in Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the Securities Act.**